8 completed. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
Follow Health: new trials by email Literature Review of Health trials Research Report on Health
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects UI009, UIC202005 - Health | Phase 1 | Completed | Korea United Pharm. Inc. | 30 | 2024-10-24 | 2025-08-08 |
| Safety and Tolerability Evaluationof Phascolarcobacterium Faecium Bacterium P. faecium - Health, Obesity Type 2 Diabetes Mellitus | Phase 1 | Completed | Spanish National Research Council | 20 | 2024-02-01 | 2025-12-16 |
| DBM-1152A Inhalation Solution in Chinese Healthy Subjects DBM-1152A Inhalation Solution, Placebo - Health, Health Adult Subjects | Phase 1 | Completed | Joincare Pharmaceutical Group Industry Co., Ltd | 44 | 2023-12-24 | 2026-03-03 |
| Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica), Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia) - Health | Phase 1 | Completed | Dexa Medica Group | 24 | 2021-04-15 | 2025-02-10 |
| A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers. Dinalbuphine sebacate, Nalbuphine HCl - Health | Phase 1 | Completed | Lumosa Therapeutics Co., Ltd. | 24 | 2020-01-31 | 2021-11-19 |
| The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects Brexpiprazole - Health | Phase 1 | Completed | Otsuka Beijing Research Institute | 30 | 2019-04-07 | 2023-11-01 |
| Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers INO-8875, Placebo control - Health | Phase 1 | Completed | Inotek Pharmaceuticals Corporation | 70 | 2010-05-01 | 2012-04-30 |
| A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers JNJ-40346527/Placebo, JNJ-40346527 - Health | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 120 | 2010-01-01 | 2013-09-04 |
Asthma (1) · Obesity (1) · Overweight (1) · Pulmonary Disease, Chronic Obstructive (1)
Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Bronchial Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathologic Processes (1) · Respiratory Hypersensitivity (1)
INO-8875 (1) · JNJ-40346527 (1) · Nalbuphine (1) · Product Packaging (1) · apixaban (1) · brexpiprazole (1) · sebacoyl dinalbuphine ester (1)
Dexa Medica Group (1) · Inotek Pharmaceuticals Corporation (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Joincare Pharmaceutical Group Industry Co., Ltd (1) · Korea United Pharm. Inc. (1) · Lumosa Therapeutics Co., Ltd. (1) · Otsuka Beijing Research Institute (1) · Spanish National Research Council (1)
China (2) · United States (2) · Belgium (1) · Indonesia (1) · South Korea (1) · Spain (1)
Danang A Yunaidi (1) · David Nguyen, MD (1) · Tao Jiang, Master (1) · Yanmin Wu (1) · Yolanda Sanz, Professor (1)